pharmaceutical industry

The Council of the European Union has adopted new legislation aimed at making the EU pharmaceutical sector fairer and more competitive. The so-called pharma package reforms the framework for medicines in the bloc, touching on access, availability and the attractiveness of Europe as a place to develop and produce drugs. It marks a major step in the EU's effort to modernise rules that have been in place for two decades.

Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.

Kobayashi Pharmaceutical, the Japanese maker at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer worth more than ¥500 billion. The move would mark a major development for a company whose reputation and finances were badly damaged by the scandal, and market watchers are closely following what a takeover could mean for its future.

China plans to open new manufacturing facilities in Kazakhstan, including plants producing robots, cars and pharmaceuticals. The projects deepen economic and industrial cooperation between the two neighbours and fit Kazakhstan's push to attract foreign investment and diversify its economy beyond raw materials. The announcement is drawing attention across regional media as a sign of expanding Chinese industrial presence in Central Asia.